Download CURRICULUM VITAE - Test - University of South Florida

i
CURRICULUM VITAE
NAME:
ADDRESS:
THERESA ANN ZESIEWICZ, MD FAAN
12901 Bruce B. Downs Blvd., MDC 55
Tampa, Florida 33612
Work (813) 974-5909
PHONE NUMBERS:
ACADEMIC APPOINTMENTS:
1995 – 2001
Assistant Professor of Neurology, University of South Florida
2001 –2008
Associate Professor of Neurology (tenured), University of South Florida
2005 –present Associate Professor of Pharmacology and Molecular Therapeutics, University of South
Florida
2007-present Fellow, American Academy of Neurology
2008 - present Professor of Neurology, University of South Florida (tenured)
EDUCATION:
1978 – 1982
1984 – 1988
TRAINING:
1988 – 1989
1989 – 1991
1991 – 1992
1993 – 1995
B.S., Biology
M.D.
St. Peter’s College, Jersey City New Jersey
University of Medicine and Dentistry of New Jersey
Newark, New Jersey
Medical Resident, PGY I, University of Medicine and Dentistry of New Jersey
Newark, NJ
Neurology Resident, PGY II-III, SUNY Downstate Medical Center
Brooklyn, NY
Chief Resident, PGY IV, SUNY Downstate Medical Center
Brooklyn, NY
Fellowship in Movement Disorders
University of South Florida, Tampa, Florida
LICENSURE:
Florida State License #ME0064808
CERTIFICATION:
Diplomate, National Board of Medical Examiners
Board Certified in Neurology, American Board of Psychiatry and Neurology, recertified
OUTSIDE SERVICE FUNCTIONS:
American Academy of Neurology (AAN):
American Academy of Neurology Topic Chair, Movement Disorders for Annual Meeting (20092010, 2010-2011, 2011-2012)
ii
Member, Quality Standards Subcommittee (QSS) (2007 – present)
Member, QSS, Practice Parameter in Parkinson’s Disease (2002 to 2006)
Chair, QSS, Practice Parameter in Essential Tremor (2001 to 2005, 2007-present (update),
Chair, Practice Parameter in Non-motor Symptoms of Parkinson’s disease, Restless Legs
Syndrome, Tardive Dyskinesia Practice Parameters for American Academy of Neurology
Moderator, Scientific Highlights Session on Movement Disorders (2008)
Reviewer, Scientific Program Abstracts (2008)
Auditor, Movement Disorders, Hyperkinetic Disorders session (2008)
Director, Movement Disorders Therapy Scientific Program (7TP.002) (2008)
Member, American Academy of Neurology Education Committee (2008)
Agency for Healthcare Research and Quality (AHRQ):
Member, Quality Standard Subcommittee, Review of Parkinson’s Disease (2001 – 2002)
Southeast Parkinson Disease Association, Inc.:
Director of Research (A Chapter of the National Parkinson Foundation, Serving the Central and
Northern Florida areas)
Other Academic Appointments:
2002 – 2004
2006 – 2008
2006 – present
2006 – present
2006 – 2007
2008---present
2008---present
2008---2010
2011-present
Director, 4th year Student Clerkship, University of South Florida
Associate Director, Parkinson’s Disease and Movement Disorders Center,
University of South Florida
Center Director, Southeast Parkinson’s Disease Consortium, James A Haley Veteran’s
Administration Hospital
Director, 4th year Medical Student Clerkship, University of South Florida
Co-Director, Scholarly Concentration for Research, University of South Florida
Director, Parkinson’s Disease PADRECC, James A. Haley Veterans Administration
Tampa, Florida
Director, USF Ataxia Research Center
Director of Clinical Research, Parkinson’s Research Foundation
Founder and Director, Frances J. Zesiewicz Center and Foundation for Parkinson’s
Disease, University of South Florida, Carol Morsani Center, Tampa, Florida
HOSPITAL APPOINTMENTS:
1995 – present Attending Physician, Tampa General Hospital
1993 – 2002
Director, Neurology for Health Park Specialty Clinic
HOSPITAL AND UNIVERSITY SERVICE
Neurology Department University of South Florida:
1996 - present Director of 2nd Year Medical Student Neurology Course
1999 - 2000
Assistant Director of Neurology of Medical Students IV
2001 - present Member Promotions and Tenure Committee, Department of Neurology
iii
2001 - present Chair, Promotions and Tenure Committee for Volunteer Faculty, Department of
Neurology
2002 - present Member, Chair Search Committee, Department of Neurology
2003 - present Reviewer, National Board of Medical Examiners, 4th year Medical Student Examination
SOCIETY MEMBERSHIPS:
American Academy of Neurology (AAN), 1993 – present (Fellow since 2006)
Movement Disorders Society (MDS), 1993 - present
American Medical Association (AMA), 1995 - present
Parkinson's Study Group (PSG), 1997 - present
American Board of Psychiatry and Neurology (ABPN), (Diplomat 1998 – present)
REFEREE SERVICES:
Ad hoc referee for the following journals:
Neurology, Movement Disorders Journal, Acta Neurologica Scandinavia, Clinical Neuropharmacology,
Current Opinions in Neurology, Parkinson’s Disease and Related Disorders, European Neurology,
Journal of Neurology
AWARDS AND HONORS:
1999
Physician-Clinician of the Year, University of South Florida
2002
Faculty Scholar-Scientist of the Year, University of South Florida
2005 - 2006
Million Dollar Researcher, Silver Member, University of South Florida
2006
Elected to “Fellow” status in the American Academy of Neurology (AAN)
RESEARCH SUPPORT:
Active
Principal Investigator: Theresa Zesiewicz
Source: Friedreich’s Ataxia Research Alliance
Title of Project: “Clinical Outcome Measures in Friedreich’s Ataxia”
Dates of Project: 2010 - 2016
Aims: The primary objective of this study is to find out ways to follow progression of Friedreich’s Ataxia
(FRDA) and be able to measure clinical and biochemical changes over a short period of time.
Active
Principal Investigator: Theresa Zesiewicz
Source: Friedreich’s Ataxia Research Alliance (Investigator initiated)
Title of Project: “Natural History Biomarkers in Friedreich’s Ataxia”
Dates of Project: 2011 - 2013
Aims: The primary objective of this study is to test a series of biomarkers for sensitivity in detecting
progression in Friedreich’s Ataxia.
Active
Principal Investigator: Theresa Zesiewicz
Source: Baxter Healthcare Corporation, USF Department of Neurology (Investigator initiated)
iv
Title of Project: “A Pilot, Open-label Study to Determine the Safety and Efficacy of Intravenous Immune
Globulin in Treating Friedreich’s Ataxia and Spinocerebellar Ataxia”
Dates of Project: 2011 – 2012
Budget: $100,050
Aims: The primary objective of this study is to test if intravenous immunoglobulin (IVIG) helps reduce
symptoms of Friedreich’s ataxia (FA) or spinocerebellar ataxia type 3 (SCA 3).
Active
Principal Investigator: Theresa Zesiewicz
Source: National Institutes of Neurological Disorders and Stroke (NINDS)
Title of Project: “Natural history of and genetic modifiers in Spinocerebellar Ataxias (SCA)”
Dates of Project: 2010 - 2013
Total Budget: $15,000
Aims: The primary objective of this study is to bring together a group of experts in the field of SCA for
the purpose of learning more about the disease, finding out how your disease progresses over time, and
what may be the best way to measure the progression. Also, the study will try to find out if some genes,
other than the gene that is abnormal in your disease, have any effect on the way the disease behaves.
Active
Principal Investigator: Theresa Zesiewicz
Source: Astellas Pharmaceuticals (Investigator initiated)
Total # of sites supervised: 3
Title of Project: “A Multi-site, Double-blind, Randomized, Placebo controlled trial of Solifenacin
succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson’s Disease”
Dates of Project: 2010 - 2012
Total Budget: $202,850
Aims: The primary objective of this study is to determine if VESIcare (Solifenacin succinate) is helpful in
treating urinary incontinence and overactive bladder in Parkinson’s Disease (PD).
Active
Principal Investigator: Theresa Zesiewicz
Source: Allon Therapeutics, Inc.
Title of Project: “A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the
Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy”
Dates of Project: 2011 - 2012
Total Budget: $81,552
Aims: The primary objective of this study are to evaluate davunetide 30 mg BID relative to placebo, when
both are administered IN for 52 weeks to subjects with PSP
Completed
Principal Investigator: Theresa Zesiewicz
Source: Friedreich’s Ataxia Research Alliance; Pfizer (Investigator initiated)
Total # of sites supervised: 2
Title of Project: “Double-blind, Randomized, Placebo-Controlled pilot study of Varenicline (Chantix®)
in the Treatment of Friedreich’s Ataxia”
Total Budget: $124,278
Dates of Project: 2008 - 2010
Completed
Principal Investigator: Theresa Zesiewicz
v
Source: Bobby Allison Ataxia Research Center; National Ataxia Foundation; Pfizer (Investigator
initiated)
Total # of sites supervised: 2
Title of Project: “A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the
Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Types 1,2,3,and 6”
Total Budget: $149,918
Dates of Project: 2008 - 2011
Completed
Principal Investigator: Theresa Zesiewicz
Source: Southern Illinois University
Title of Project: “Validation of the TRG Essential Tremor Rating Scale (TETRAS)”
Total Budget: $14,550
Dates of Project: 2010-2011
Completed
Principal Investigator: Theresa Zesiewicz
Source: Pfizer (Investigator initiated)
Total # of sites supervised: 6
Title of Project: “A multi-site, double-blind, randomized, placebo-controlled, crossover study of
pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor”
Total Budget: $188,125
Dates of Project: 2007-2010
Completed
Principal Investigator: Theresa Zesiewicz
Source: Boehringer Ingelheim
Title of Project: “A two year open label, randomized, parallel group, blinded assessment ophthalmologic
safety study of pramipexole IR versus ropinirole in early Parkinson’s Disease patients” Protocol #
248.538.
Total Budget: $425,802
Dates of Project: 2007 - 2010
Completed
Principal Investigator: Theresa Zesiewicz
Source: Investigator initiated
Title of Project: “Development and Validation of a Rapid Assessment Tool (the USF Coin Stacking Test)
for Essential Tremor”
Dates of Project: 2007 - 2008
Completed
Principal Investigator: Theresa Zesiewicz
Source: National Institutes of Health. RAND, UCLA Department of Neurology
Title of Project: “Quality of Life Outcomes in Neurological Disorders”
Total Budget: $69,943
Dates of Project: 2007 - 2008
Completed
Principal Investigator: Theresa Zesiewicz
Source: Investigator initiated
Title of Project: “Pregabalin (Lyrica) for the Treatment of Essential Tremor”
vi
Dates of Project: 2006 - 2008
Completed
Principal Investigator: Theresa Zesiewicz
Source: Merck KgaA
Title of Project: “An open-label, Multicenter, Multinational Phase III follow-up Study to investigate the
long-term Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients with Parkinson’s Disease Suffering
from Treatment Associate Dyskinesia (PADDY-O)”
Total Budget: $49,400
Dates of Project: 2005 - 2007
Completed
Principal Investigator: Theresa Zesiewicz
Source: Investigator initiated
Title of Project: “Prevalence and Treatment of Non-Motor Symptoms in Parkinson’s Disease”
Total Budget: $0
Dates of Project: 2005 - 2006
Completed
Principal Investigator: Theresa Zesiewicz
Source: Novartis
Title of Project: “A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the
effect of fixed dose Stalevo® 100 (t.i.d.) vs. immediate release carbidopa/levodopa 25/100 mg (t.i.d.) in
Parkinson’s disease patients requiring levodopa”
Total Budget: $116,900
Dates of Project: 2005 - 2007
Completed
Principal Investigator: Theresa Zesiewicz
Source: Investigator initiated
Title of Project: “Stress and Marital problems in Parkinson’s Disease and Essential Tremor”
Dates of Project: 2005 - 2007
Completed
Principal Investigator: Theresa Zesiewicz
Source: Investigator initiated
Title of Project: “A Double-blind, Placebo-controlled trial of Zonisamide (Zonegran) in the treatment of
Essential Tremor”
Total Budget: $0
Dates of Project: 2005 - 2006
Completed
Principal Investigator: Theresa Zesiewicz
Source: Merck KgaA
Title of Project: “A double-blind, placebo-controlled, multicenter, multinational Phase III study to
evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering
from treatment-associated dyskinesia (PADDY 2)”
Total Budget: $0
Dates of Project: 2004 - 2006
vii
“A multi-site, double-blind, randomized, placebo-controlled study of pregabalin (Lyrica, PGB) in the
Treatment of Essential Tremor”
Pfizer (PI) $188,125
“Randomized, Double-blind, placebo-controlled trial of Lubiprostone in the treatment of constipation
associated with Parkinson’s disease.”
Takeda (PI) $101,205
“A two year open label, randomized, parallel group, blinded assessment ophthalmologic safety study of
pramipexole IR versus ropinirole in early Parkinson’s Disease patients”
Boehringer Ingelheim, Protocol # 248.538. $431,905
“An open-label, Multicenter, Multinational Phase III follow-up Study to investigate the long-term Safety
and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients with Parkinson’s Disease Suffering from Treatment
Associate Dyskinesia (PADDY-O)”
Merck KgaA $647,595
“A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and
efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatmentassociated dyskinesia (PADDY 2)”
Merck KgaA $175,600
“A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early
Parkinson’s Disease Patients (Study for Proof of Concept in Early Parkinson’s Disease of a Triple
Reuptake Inhibitor, NS 2330 / SCEPTRE)”
Boehringer Ingelheim, Protocol # 1198.100 (PI) $218,530
“A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed
dose Stalevo® 100 (t.i.d.) vs. immediate release carbidopa/levodopa 25/100 mg (t.i.d.) in Parkinson’s
disease patients requiring levodopa”
Novartis (PI) $129,206
“Onset of Motor Complications”
Glaxo-Smith Kline, 101468/228 (PI) $114,023
“Progression and Health Impacts of Parkinson’s Disease Motor and Non-motor Manifestations”
National Institutes of Health (Co-Investigator)
“Olanzapine vs Placebo for Treatment Associated Psychosis in Patients with Parksinon’s Disease”
Eli Lilly (PI) $94,440
“TVP-1012 Tolerability of TVP-1012, a Novel MAO-B Inhibitor, in Parkinsonian patients”
Lemmon Company (Co-PI)
“Open Label, Randomized, Parallel Group Comparison of Tolcapone and Pergolide Given in
Combination with Sinemet in Parkinsonian Patients who Exhibit End of Dose “wearing off”, With
Follow-Up Extension of Tolcapone”
Hoffman-LaRoche (Co-PI)
“Open-Label Study of Safety and Tolerability of Transdermal Selegiline in Mild to Moderate Parkinson's
Disease”
viii
Somerset Pharmaceuticals (Co-PI)
“Sertraline for the Treatment of Depression in Non-Fluctuating Parkinson’s Disease Patients”
Pfizer Pharmaceuticals (Co-PI)
“A Prospective, Randomized, Parallel Group, Double-Blind Placebo-Controlled MultiCenter Study to
Evaluate the Short-Term Efficacy and Safety of Entacapone Administered Together with Levodopa in
Patients with Parkinson’s Disease Without Motor Fluctuations”
Sandoz (Co-PI)
“A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study for the Safety,
Tolerability and Efficacy of Daily, Oral Doses or Remacemide Hydrochloride in Patients with Early
Parksinon’s Disease”
Astra Merch, Inc. (Co-PI)
“Clinical Investigation of Deep Brain Stimulation for Treatment of Tremor Using the Medtronic Model
3382 DBS Lead and Itrell II System”
Medtronic (Co-PI)
“Double-Blind, Placebo-Controlled, Parallel-Group Comparison to Assess the Safety, Tolerance and
Efficacy of Pramipexole in Advanced Parkinson’s Disease (0679) and to Assess Long Term Safety with
Open-Label Pramipexole”
Boehringer Ingelheim (Co-PI)
“Ropinirole-Pramipexole Switching Study”
Smith-Kline Beecham (Co-PI)
“A Multicenter, Randomized, Double-blind, Parallel Group Pilot Study Comparing TV-1203/Carbidopa
Dispersible Tablets with Standard Levodopa/Carbidopa Tablets in Advanced Parkinson's Disease (PD)
Patients with Response Fluctuations”
Parkinson Study Group/TEVA Pharmaceuticals (Co-PI)
“A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter, Exploratory
Study of the Safety and Efficacy of KW-6002 as Adjunctive Therapy in Patients with Parkinson's Disease
Who Have Motor Response Complications on Levodopa/Carbidopa”
Kyowa Pharmaceuticals (Co-PI)
“A Multicenter, Open-label, Phase III Study for the Safety, Tolerability and Clinical Effect of Rasagiline
Mesylate in Patients with Parkinson's Disease”
TEVA Pharmaceuticals (Co-PI)
“Parkinson's Research: The Organized Genetics Initiative (PROGENI)”
Parkinson Study Group/National Institutes of Health (Co-PI)
“A multicentre, multinational, randomized, double-blind, placebo-controlled, parallel-group, dose finding
study to investigate the anti-dyskinetic efficacy and safety of Sarizotan in Parkinson patients with L-dopainduced dyskinesia”
Merck KgaA (PI) EMR62 225-013 $127,300
ix
“A Multicenter, US and Canada, Double Blind, Randomized, Placebo-Controlled, Parallel Group Study,
for the Efficacy, Tolerability and Safety of Rasagiline Mesylate in Levodopa treated Parkinson’s Disease
Patients with Motor Fluctuations”
Parkinson Study Group/TEVA Neuroscience (Co-PI)
“An Active Extension of the TVP-1012/133 (PRESTO) Study—A Bi-national, Multicenter, DoubleBlind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced
Parkinson’s Disease (PD) Patients with Motor Fluctuations Treated with Chronic Levodopa/Carbidopa
Therapy”
Parkinson Study Group/TEVA Neuroscience (Co-PI)
“Study of the safety, tolerability and efficacy of Spheramine implanted bilaterally into the
postcommissural putamen of patients with advanced Parkinson’s disease”
Berlex Laboratories (Co-PI)
“Glutathione (GSH) In The Treatment of Parkinson’s Disease”
Wellness Pharmaceutical (Co-PI)
“Pilot Huntington At Risk Observational Study (PHAROS)”
Huntington Study Group (Co-PI)
“A non-interventional follow-up study to observe the long term outcome of Parkinson’s disease in
patients who completed Study SK&F 101468/056 or Study SK&F 101468125”
SmithKline Beecham (Co-PI)
“A Double-Blind Controlled, MultiCenter, Clinical Trial of the Safety and Efficacy of transplanted fetal
porcine cells in patients with Parkinson’s disease”
Diacrin/Genzyme, LLC (Co-PI)
“Extended Phase II Clinical Study of: Protocol N. PD 96-1101, A Double blind, randomized, controlled,
multicenter clinical trial of the safety and efficacy of transplanted fetal porcine cells in patients with
Parkinson’s disease”
Diacrin/Genzyme, LLC (Co-PI)
“A Comparison of the Efficacy and Safety of Topiramate Versus Placebo In the Treatment of Essential
Tremor”
Ortho-McNeil Pharmaceutical, Inc. (Co-PI)
“A multi-national, multi-center, double-blind, placebo controlled study to evaluate the efficacy,
tolerability and safety of glatiramer acetate for injection in Primary Progressive Multiple Sclerosis
patients”
Teva Neuroscience, LLC (Co-PI)
“A double-blind, multicenter, flexible dose, l-dopa controlled study of ropinirole to investigate A)
neuroprotective effect as measured by 3D Pet scanning and B) ophthalmological safety, in patients with
early Parkinson’s disease”
SmithKline Beecham (Co-PI)
“A Randomized Double-Blind Parallel-Group Study to Compare the Safety and Efficacy of Zydis
Selegiline 1.25 mg to 2.5 mg QD with Placebo as an Adjunct in the Management of Parkinsonian Patients
x
Being Treated with Levodopa who Exhibit Deterioration in the Quality of Their Response to this
Therapy”
Scherer/DDS (Co-PI)
“An Open Extension Study of the Safety and Efficacy of Zydis Selegiline 1.25 to 2.5 mag as an Adjunct
in the Management of Parkinsonian Patient Being Treated with Levodopa”
Scherer/DDS (Co-PI)
POST-DOCTORAL FELLOWS AND STUDENTS:
Alpa Patel-Larson (MPH 1997-1998), Summer Carter-Wolfrath (MPSH 2000 – 2002), Kelly Sullivan
(MSPH, PhD 2002 – present), Apurva Shah MD (2003 – 2004), Amit Patchak MD (2004 – 2006)
THESIS COMMITTEE SERVICE, USF:
Thesis committee member for the following USF MSPH candidates:
Summer Carter-Wolfrath (2002), Kelly Sullivan (2002), Alpa Patel-Larson (2001)
Dissertation committee member for the following USF PhD candidate: Kelly L. Sullivan, (2008-2012)
Peer-Reviewed Publications
1. Wecker L, Engberg ME, Philpot RM, Lambert CS, Kang CW, Antilla JC, Bickford
P, Hudson C, Zesiewicz TA, Rowell PP. Neuronal Nicotinic Receptor Agonists
Improve Gait and Balance in Olivocerebellar Ataxia. Neuropharmacology 2013, In
Press.
2. Shaw JD, Allison KG, Staffetti JS, Zesiewicz TA. Diagnosis and Treatment of
Essential Tremor. Neurodegenerative Disease Management 2013, In Press.
3. Zesiewicz TA, Shaw JD, Allison KG, Staffetti JS, Okun MS, Sullivan KL. Update on
Treatment of Essential Tremor. Current Treatment Options in Neurology 2013, In
Press.
4. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA.
Evidence-based guideline: Treatment of tardive syndromes. Report of the Guideline
Development Subcommittee of the American Academy of Neurology. Neurology
(Submitted for Publication).
5. Zesiewicz TA, Elble FH, Louis ED, Gronseth GS, Ondo WG, Dewey RB, Okun MS,
Sullivan KL, Weiner WJ. Evidence-Based Guideline Update: Treatment of Essential Tremor.
Report of the Quality Standards Subcommittee of the American Academy of Neurology.
Neurology, October, 2011 (In Press)
xi
6. Elm JJ; NINDS NET-PD Investigators. Design innovations and baseline findings in a longterm Parkinson's trial: the National Institute of Neurological Disorders and Stroke
Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord. 2012
Oct;27(12):1513-21. doi: 10.1002/mds.25175.
7. Dempsey L, Karver M, Zesiewicz TA. Self-Perceived Burden as a Mediator of
Depression Symptoms Amongst Individuals Living with a Movement Disorder. J
Clinical Psychology 2012, In Press.
8. Favilla CG, Topiol DD, Zesiewicz TA, Wagle Shukla A, Foote KD, Jacobson CE
4th, Okun MS. Impact of discontinuing tremor suppressing medications following
thalamic deep brain stimulation. Parkinsonism Relat Disord. 2013 Feb;19(2):171-5.
doi: 10.1016/j.parkreldis.2012.09.002. Epub 2012 Oct 11.
9. Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, Lewitt P, Lyons K,
Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R,
Zesiewicz T. Reliability of a new scale for essential tremor. Mov Disord. 2012
Oct;27(12):1567-9. doi: 10.1002/mds.25162. Epub 2012 Oct 2.
10. Ondo WG, Hunter C, Davidson A, Sullivan KL, Hunter C, Jahan I, Kenney C,
Daleiden A, Miller A, Zesiewicz TA. Sullivan KL, Jahan I, Miller A. PlaceboControlled Trial of Lubiprostone for Constipation Associated with Parkinson's
Disease. Neurology 2012, In Press.
11. Snyder M, Seyer L, Lynch DR, Resnick A, Zesiewicz, TA. Cardiac Dysfunction
Exacerbated by Endocrinopathies in Friedreich’s Ataxia: A Case Series. Journal of
Child Neurology 2012, In Press.
12. Carranza M, Synder M, Elble R, Zesiewicz TA. Methodological Issues in Essential Tremor.
Tremor and Hyperkinetic Disorders 2012, In Press.
13. Zesiewicz, TA. The controversy over levodopa toxicity. Nature Reviews 2011 (In Press).
14. Zesiewicz TA, Greenstein P, Sullivan KL. Double-blind, placebo-controlled trial of
Varenicline in the treatment of Spinocerebellar Ataxia Type 3. Neurology, 2011 (In Press).
15. Cimino CR, Siders CA, Zesiewicz, TA. Depressive Symptoms in Parkinson’s Disease:
Degree of Association and Rate of Agreement of Clinician-Based and Self-Report Measures.
Journal of Geriatric Psychiatry and Neurology 2011, In Press.
xii
16. Resnick AS, Okun MS, Malapira T, Smith D, Vale F, Sullivan K, Miller A, Jahan I,
Zesiewicz, T. Sustained Medication Reduction Following Unilateral VIM Thalamic
Stimulation for Essential Tremor. Tremor and Other Hyperkinetic Disorders, 2011, In Press.
17. Chiong-Rivero H, Ryan GW, Flippen C, Bordelon Y, Szumski NR, Zesiewicz TA, Vassar S,
Weidmer B, García RE, Bradley M, Vickrey BG. Patients' and caregivers' experiences of the
impact of Parkinson's disease on health status.Patient Relat Outcome Meas. 2011
Mar;2011(2):57-70.
18. Friedman JH, Agarwal P, Alcalay R, Black KJ, Chou KL, Cote L, Dayalu P, Frank S,
Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D,
Sanchez-Ramos J, Simon DK, Simuni T, Sutton J, Tuite P, Weintraub D, Zesiewicz T.
Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced
Hallucinations, Delusions, and Compulsive. Int J Neurosci. 2011 Jun 10. [Epub ahead of
print]
19. Sanchez-Ramos J, Reimer D, Zesiewicz T, Sullivan K, Nausieda PA. Quantitative analysis of
tremors in welders. Int J Environ Res Public Health. 2011 May;8(5):1478-90. Epub 2011
May 10.
20. Limotai N, Go C, Oyama G, Hwynn N, Zesiewicz T, Foote K, Bhidayasiri R, Malaty I,
Zeilman P, Rodriguez R, Okun MS. Mixed results for GPi-DBS in the treatment of craniofacial and cranio-cervical dystonia symptoms. J Neurol. 2011 May 7. [Epub ahead of print]
21. Zesiewicz TA, Elble FH, Louis ED, Gronseth GS, Ondo WG, Dewey RB, Okun MS,
Sullivan KL, Weiner WJ. Evidence-Based Guideline Update: Treatment of Essential Tremor.
Report of the Quality Standards Subcommittee of the American Academy of Neurology.
Neurology, October, 2011 (In Press)
22. Oyama G, Okun MS, Zesiewicz TA, Tamsea T, Romrella J, Zeilman P, Foot KD. Delays in
Clinical Improvement in Deep Brain Stimulation Related Subdural Hematoma. Journal
Neurology, Neurosurgery, and Psychiatry, Accepted January 2011, In Press.
23. Zesiewicz TA, Miller A, Dempsey L, Sullivan KL. Overview of Essential Tremor.
Neuropsychiatric Disease and Treatment, Neuropsychiatr Dis Treat. 2010 Sep 7;6:401-8.
24. Garbuzova-Davis S, Woods RL 3rd, Louis MK, Zesiewicz TA, Kuzmin-Nichols N, Sullivan
KL, Miller AM, Hernandez-Ontiveros DG, Sanberg PR.
Reduction of circulating endothelial cells in peripheral blood of ALS patients. PLoS One.
2010 May 12;5(5):e10614.
25. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early
Parkinson's disease. Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow
W, Gray AM, Adams B, Earl NL; 228 Study Investigators. Mov Disord. 2010 May
15;25(7):858-66.
26. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease.
Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF,
Nichols WC, Foroud T; Parkinson Study Group-PROGENI Investigators. BMC Med Genet.
2010 Apr 1;11:53.
xiii
27. Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, Miyasaki J,
Iverson DJ, Weiner WJ. Practice Parameter: treatment of nonmotor symptoms of Parkinson
disease: report of the Quality Standards Subcommittee of the American Academy of
Neurology Quality Standards Subcommittee of the American Academy of Neurology.
Neurology. 2010 Mar 16;74(11):924-31.
28. Jahan I, Hauser RA, Sullivan KL, Miller A, Zesiewicz TA. Sleep disorders in Parkinson's
disease. Neuropsychiatr Dis Treat. 2009;5:535-40. Epub 2009 Nov 2.
29. Saleh IA, Zesiewicz TA, Xie Y, Sullivan KL, Miller AM, Kuzman-Nichols N, Sanberg PR,
Garbuzova-Davis S. Evaluation of Humoral Immune Response in Adaptive Immunity in ALS
Patients During Disease Progression. Journal of Immunology 2009, In Press.
30. Zesiewicz TA, Evatt M. Potential Influences of Complementary Therapy on Motor and NonMotor Complications in Parkinson’s Disease. CNS Drugs 2009, In Press.
31. Fleischman D, Madan G, Zesiewicz TA, Fleischman M. Stiff-person syndrome: Commonly
mistaken for hysterical paralysis. Clin Neurol Neurosurg. 2009 May 25.
32. Nichols WC, Kissell DK, Pankratz N, Pauciulo MW, Elsaesser VE, Clark KA, Halter CA,
Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T; Parkinson Study Group-PROGENI
Investigators. Variation in GIGYF2 is not associated with Parkinson disease.Neurology. 2009
Jun 2;72(22):1886-92. Epub 2009 Mar 11.
33. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRSTSTEP Study Group. Double-blind trial of levodopa/carbidopa/entacapone versus
levodopa/carbidopa in early Parkinson's disease. Mov Disord. 2009 Mar 15;24(4):541-50.
34. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at
onset. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA,
Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T; Parkinson Study Group-PROGENI
Investigators. Neurology. 2009 Jan 27;72(4):310-6. Epub 2008 Nov 5.
35. Genomewide association study for susceptibility genes contributing to familial Parkinson
disease. Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, Doheny KF,
Gusella JF, Nichols WC, Foroud T, Myers RH; PSG-PROGENI and GenePD Investigators,
Coordinators and Molecular Genetic Laboratories. Hum Genet. 2009 Jan;124(6):593-605.
Epub 2008 Nov 6.
36. Levetiracetam for stiff-person syndrome: report of 2 patients. Shimberg WR, Patel NB,
Sullivan KL, Hauser RA, Zesiewicz TA. Clin Neuropharmacol. 2008 Sep-Oct;31(5):301-2.
37. Clinical correlates of depressive symptoms in familial Parkinson's disease. Pankratz N,
Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T; Parkinson's Study
Group-PROGENI Investigators. Mov Disord. 2008 Nov 15;23(15):2216-23.
xiv
38. Zesiewicz TA, Sullivan KL, Gooch CL, Lynch DL. Subjective Improvement in
Proprioception in Two Atypical Friedreich’s Ataxia Patients Treated with Varenicline
(Chantix®). Journal of Clinical Neuromuscular Disease. Accepted October 2008.
39. Zesiewicz TA, Sullivan KL, Gooch CL.Red flags to spot the parkinsonian variant of multiple
system atrophy.Nat Clin Pract Neurol. 2008 Aug 12.
40. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson
Study Group ELLDOPA Investigators.Fatigue in levodopa-naive subjects with Parkinson
disease. Neurology. 2008 Aug 12;71(7):481-5.
41. Zesiewicz TA, Sullivan KL. Treatment of Ataxia and Imbalance with Varenicline
(Chantix®): Report of 2 Patients with Spinocerebellar Ataxia (Types 3 and 14). Clinical
Neuropharmacology 2008, In Press.
42. Espay A, Okun M, Zesiewicz TA, Foote K. Deep brain stimulation of the ventral
intermediate nucleus of the thalamus in medically refractory orthostatic tremor. Movement
Disorders 2008, In Press.
43. Zesiewicz TA, Sullivan KL, Freeman A, Juncos JL. Treatment of imbalance with varenicline
(Chantix): report of a patient with Fragile X Tremor Ataxia Syndrome (FXTAS). Acta
Neurologica Scandinavica, Accepted May 2008, In Press.
44. Zesiewicz TA, Hauser RA, Freeman A, Sullivan KL, Miller AM, Halim T. Fentanyl-Induced
Bradykinesia and Rigidity in a Parkinson’s Disease Patient Following Deep Brain
Stimulation. Clinical Neuropharmacology, Accepted 2008, In Press.
45. Shimberg WR, Patel NB, Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam for StiffPerson Syndrome: Report of 2 Patients. Clinical Neuropharmacology 2008
(September/October)
46. Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as
a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome type
1. Clinical Rheumatology 2008 Mar;27(3):389-390.
47. Zesiewicz TA. Dopamine Agonists in Parkinson’s Disease. The Consultant 2008.
48. Zesiewicz TA. Low dose Topiramate (Topamax) in the treatment of essential tremor. Clin
Neuropharmacol 2007 Jul-Aug;30(4):247-8.
49. Zesiewicz TA, Ward CL, Hauser RA, Salemi J, Siraj S, Wilson MC, Sullivan KL. A pilot,
double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential
tremor. Mov Disord. 2007 Aug 15;22(11):1660-3.
50. Zesiewicz TA, Sullivan KL, Benes LM, Smith SA, Ward CL, Hauser RA. Delayed Thalamic
Intracranial Hemorrhage in an Essential Tremor Patient following Deep Brain Stimulation.
Eur Neuro 2008;59(3-4):187-9.
xv
51. Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced Dyskinesia in Parkinson’s
Disease: Epidemiology, Etiology, and Treatment. Curr Neurol Neurosci Rep. 2007;7(4):30210.
52. Zesiewicz TA, Sullivan KL, Ward CL, Hauser RA. Tiagabine and Exacerbation of Essential
Tremor. Mov Disord. 2007 Oct 31;22(14):2132-3.
53. Zesiewicz TA, Patel-Larson A, Hauser RA, Sullivan KL. Social Security Disability Insurance
(SSDI) in Parkinson’s Disease. Disability and Rehabilitation 2007 Dec 30;29(24):1934-6.
54. Hauser RA, Zesiewicz TA. Treatment of Early Parkinson’s disease. The Lancet 2007, in
press.
55. Zesiewicz TA, Sullivan KL, Hauser RA. Non-motor symptoms in Parkinson’s disease. Exp
Rev Neurotherapeutics 2006;6(12): 1811-22.
56. Sullivan KL, Ward CL, Hauser RA, Zesiewicz TA. Prevalence and Treatment of Non-Motor
Symptoms in Parkinson's Disease. Parkinsonism Relat Disord. 2007 Dec;13(8):545.
57. Zesiewicz TA, Ward CL, Hauser RA, Sanchez-Ramos J, Staffetti JF, Sullivan KL. A Doubleblind, Placebo-Controlled Trial of Zonisamide (Zonegran) in the Treatment of Essential
Tremor. Mov Disord. 2007 Jan 15;22(2):279-82.
58. Zesiewicz TA, Ward CL, Hauser RA, Pease Campbell JA, Sullivan KL. Pregabalin (Lyrica)
in the Treatment of Essential Tremor. Movement Disorders. 2006 Jan; 22(1):139-141.
59. Zesiewicz TA, Hauser RA. Treatment of Parkinson’s Disease. Continuum, Fall 2006.
60. Sullivan KL, Ward CL, Zesiewicz TA. Zonisamide-Induced Mania in an Essential Tremor
Patient. J Clin Psychopharmacol. 2006;26(4):439-40.
61. Hauser RA, Zesiewicz TA. Clinical trials aimed at detecting neuroprotection in Parkinson's
disease. Neurology. 2006 May 23;66(10 Suppl 4):S58-68.
62. Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. An Open-Label Pilot Study of
Levetiracetam (Keppra) for the Treatment of Chorea in Huntington’s Disease. Clin
Neuropharmacol. 2005 Jul-Aug;28(4):188-90.
63. Zesiewicz TA, Tullidge A, Tidwell J, Sullivan KL, Hauser RA. Topiramate-Induced
Psychosis in Essential Tremor Patients: Report of 2 Cases. Clin Neuropharmacol. 2006 MayJun;29(3):168-9.
64. Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA. The Controversy Concerning
Plasma Homocysteine in Parkinson’s Disease Patients Treated with Levodopa alone or with
Entacapone: Effects of Vitamin Status. Clin Neuropharmacol. 2006 May-Jun;29(3):106-11.
65. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ; Quality
Standards Subcommittee of the American Academy of Neurology. Practice Parameter:
diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of
the Quality Standards Subcommittee of the American Academy of Neurology. Neurology.
2006 Apr 11;66(7):968-75.
xvi
66. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ; Quality
Standards Subcommittee of the American Academy of Neurology. Practice Parameter:
neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based
review): report of the Quality Standards Subcommittee of the American Academy of
Neurology. Neurology. 2006 Apr 11;66(7):976-82. Erratum in: Neurology. 2006 Jul
25;67(2):299.
67. Zesiewicz TA, Sullivan KL, Hauser RA. Chorea induced by Lamotrigine. J Child Neurol.
2006 Apr;21(4):357.
68. Wolfrath SC, Borenstein AR, Schwartz S, Hauser RA, Sullivan KL, Zesiewicz TA. Use of
Nutritional Supplements in Parkinson’s Disease Patients. Mov Disord. 2006 Aug;21(8):1098101.
69. Zesiewicz TA, Pathak A, Sullivan KL, Shamayev M, Hauser RA. Treatment of chorea with
levetiracetam. Eur J Clin Pharmacol 2006 Jan;62(1):87.
70. Zesiewicz TA, Sullivan KL, Hauser RA. Vascular hemichorea/hemiballismus and
topiramate.Mov Disord. 2006 Apr;21(4):581.
71. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the
Treatment of Constipation in Parkinson’s Disease. Mov Disord 2006 Jan;21(1):115-6.
72. Sullivan KL, Hauser RA, Louis ED, Chari G, Zesiewicz TA. Case Report: Levetiracetam for
the Treatment of Generalized Dystonia. Parkinsonism and Related Disorders 2005, July 11.
73. Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser RH. Levetiracetam-Induced
Parkinsonism in a Huntington’s Disease Patient. Clin Neuropharmacol. 2005;28(4):188-190.
74. Zesiewicz TA, Elble R, Louis ED, Sullivan KL, Hauser RA, Dewey RB Jr, Ondo WG,
Gronseth GS, Weiner WJ. Practice parameter: therapies for essential tremor: report of the
Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005
Jun 28;64(12):2008-20.
75. Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study
of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's
disease. Mov Disord. 2005 Sep;20(9):1205-9.
76. Sullivan KL, Hauser RA, Zesiewicz TA. Levetiracetam in the Treatment of Essential
Tremor. Mov Disorders 2005;20(5):640.
77. Recio MV, Hauser RA, Louis ED, Radhashakar H, Sullivan KL, Zesiewicz TA. Chorea in a
patient with cerebral palsy: treatment with levetiracetam. Mov Disord 2005; 20(6):762-4.
78. Parkinson Study Group. Levodopa and the of progression of Parkinson disease, the
ELLDOPA study. N Engl J Med. 2004 Dec 9;351(24):2498-508.
79. Zesiewicz TA, Stamey W, Sullivan KL, Hauser RA. Botulinum Toxin A for the Treatment of
Cervical Dystonia. Expert Opin Pharmacother. 2004 Sep;5(9):2017-24.
xvii
80. Zesiewicz TA, Louis ED, Sullivan KL, Menkin M, Dunne PB, Hauser RA. Substantial
Improvement in a Meige’s Syndrome Patient with Levetiracetam Treatment. Mov Disord
2004;19:1518-1521.
81. Zesiewicz TA, Strom JA, Borenstein AR, Hauser RA, Cimino CR, Fontanet H, Cintron C,
Staffetti JF, Dunne PB, Sullivan KL. Heart Failure in Parkinson’s Disease: Analysis of the
United States Medicare Current Beneficiary Survey, 1997-1999. Parkinsonism & Related
Disorders 2004;10:417-420.
82. Sullivan KL, Hauser RA, Zesiewicz TA. Essential Tremor: A Review. Neurologist. 2004
Sep;10(5):250-8.
83. Zesiewicz TA, Carter SN, Sullivan KL, Staffetti JF, Dunne PB, Hauser RA. Initial
Management of Parkinson’s Disease in a Florida Community. The Journal of Applied
Research 2004;4:95-98.
84. Zesiewicz TA, Baker MJ, Wahba M, Hauser RA. Autonomic nervous system dysfunction in
Parkinson’s disease. Curr Treat Options Neurol 2003;5:149-160.
85. Zesiewicz TA, Hauser RA. Sleep attacks and dopamine agonists for Parkinson’s disease:
What is currently known? CNS Drugs 2003;17:593-600.
86. Zesiewicz TA, Cimino CR, Malek AR, Gardner N, Leaverton PL, Dunne PB, Hauser RA.
Driving Safety in Parkinson’s Disease. Neurology 2002;59:1787-1788.
87. Zesiewicz TA, Borra S, Hauser RA. Clozapine withdrawal in a Parkinson’s disease patient.
Mov Disord. 2002 Nov;17(6):1365-7.
88. Zesiewicz TA, Hauser RA. Depression in Parkinson's disease. Cur Psychiatry Rep. 2002
Feb;4(1):69-73.
89. Zesiewicz TA, Encarnacion E, Hauser RA. Management of essential tremor. Curr Neurol
Neurosci Rep. 2002 Jul;2(4):324-30.
90. Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA. Diffuse Lewy Body Disease. Curr Treat
Options Neurol 2001;6:507-518.
91. Hauser RA, Wahba MN, Zesiewicz TA, Anderson WM. Reply. Mov Disord 2001;16:783784.
92. Zesiewicz TA, Hauser RA. Neurosurgery in Parkinson's disease. Seminars Neurol
2001;21:91-101.
93. Zesiewicz TA, Hauser RA. Phenomenology and treatment of tremor in Parkinson's disease.
Neurol Clin 2001;3:651-680.
94. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and
episodes of daytime sleep. Movement Disorders 2000;15:658-663.
95. Hauser RA, Wahba MN, Zesiewicz TA, McDowell Anderson W. Modafinil treatment of
pramipexole-associated somnolence. Mov Disord 2000;15:1269-1271.
xviii
96. Zesiewicz TA, Hauser RA. Depression in Parkinson's Disease. CNS Drugs 2000.
97. Zesiewicz TA, Helal M, Hauser RA. Sildenafil Citrate (Viagra) for the Treatment of Erectile
Dysfunction in Men with Parkinson's Disease. Mov Disorders 2000; 15(2):305-8.
98. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES,
Factor SA. A Home Diary to Assess Functional Status in Parkinson’s Patients With Motor
Fluctuations and Dyskinesia. Clin Neuropharmacol. 2000 Mar-Apr;23(2):75-81.
99. Hauser RA, Zesiewicz TA. Management of Early Parkinson's Disease. Medical Clinics of
North America. 1999;83:393-414.
100.
Zesiewicz TA, Hauser RA. Ropinirole in the treatment of Parkinson's Disease. Expert
opinion of Investigational Drugs. 1999;8:697-710.
101.
Zesiewicz TA, Gold M, Chari G, Hauser RA. Depression and Anxiety in Parkinson’s
Disease. American Journal of Geriatric Psychiatry. 1999;7:110-118.
102.
Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on
medications in Parkinson’s disease: efficacy versus usefulness. Parkinsonism & Related
Disorders 1997;3:1-6.
103.
Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s
disease. Movement Disorders 1997;12:756-759.
104.
Hauser RA, Zesiewicz TA. Manganese and chronic liver disease. Movement Disorders
1996; 11:589.
105.
Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Blood manganese
correlates with brain MRI changes in patients with liver disease. Canadian Journal of
Neurological Sciences 1996;23:95-98.
106.
Hauser RA, Zesiewicz TA. Sertraline-induced exacerbation of tics in Tourette’s
syndrome. Movement Disorders 1995;10:682-684.
107.
Hauser, RA, Zesiewicz TA, Rosemurgy AS, Martinez C, Olanow CW. Manganese
intoxication and chronic liver failure. Ann Neurol 1994;36:871-875.
108.
Jeret JS, Mandell M, Anziska B, Lipitz M, Vilceus AP, Ware JA, Zesiewicz TA. Clinical
predictors of abnormalities disclosed by computed tomography after mild head trauma.
Neurosurgery 1993;32(1):9-15, discussion 15-16.
ABSTRACTS
1. Sullivan KL, Ward CL, Hauser RA, Staffetti JF, Sanchez-Ramos J, Zesiewicz TA.
Accelerometry: variable correlation with functional impact of tremor. 60th American Academy of
Neurology Annual meeting, April 12-19 2008, Chicago, Illinois (April 16th Poster Session).
xix
2. Garbuzova-Davis SN, Zesiewicz T, Xie Y, Sullivan KL, Ward CL, James C, Willing AE,
Bickford PC, Gemma C, Hudson C, Kuzmin-Nichols N, Davis-Sanberg C, Sanberg PR. Plasma
Derived from Human Umbilical Chord Blood Modulates Mitogen-Induced Proliferation in
Mononuclear Cells Isolated from the Peripheral Blood of ALS Patients. Cell Transplantation,
2007;16(3):323.
3. Sullivan KL, Ward CL, Siraj S, Ortega M, Staffetti JF, Zesiewicz TA. Sexual dysfunction and
driving status are important predictors of marital satisifaction in Parkinson’s disease. 59th
American Academy of Neurology Annual meeting, April 29-May 5 2007, Boston, Massachusetts
(May 1st Poster Session).
4. Sullivan KL, Ward CL, Hauser RA, Dunne PB, Zesiewicz TA. Prevalence and treatment of nonmotor symptoms in Parkinson’s disease. 58th American Academy of Neurology Annual meeting,
April 1-8, 2006, San Diego, California. Presented on Wednesday, April 5th, Poster Session
P04:031.
5. Zesiewicz TA, Ward CL, Staffetti JF, Dunne PB, Sullivan KL. A double-blind, placebocontrolled trial of Zonisamide (Zonegran) in the treatment of essential tremor. 58th American
Academy of Neurology April 1-8, 2006, San Diego, California. Presented on Wednesday, April
5, S33:004.
6. Zesiewicz TA, Sullivan KL, Hauser RA, Behrouz R, Sanchez-Ramos JR. Levetiracetam (Keppra)
in the Treatment of Choreiform Movements in Huntington's Disease. American Academy of
Neurology, Miami, April 12, 2005.
7. Zesiewicz TA, Sullivan KL, Maldonado JA, Tatum WO, Hauser RA. Levetiracetam (Keppra) in
the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease. Presented at 56th
American Academy of Neurology, San Francisco, CA 2004.
8. Zesiewicz TA, Guinta B, Hauser RA, Hoffman M, Wallach P, Sullivan KL. Levodopa-Induced
Hyperhomocysteinemia and Cardiovascular Dysfunction in Parkinsons Disease. MDS Congress,
June 15, 2004, at the Palazzo dei Congressi, Rome, Italy, P599.
9. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. A Double-blind, Randomized
Trial of Tegaserod (Zelnorm) in the Treatment of Constipation in Parkinson’s Disease. MDS
Congress, June 15, 2004, at the Palazzo dei Congressi, Rome, Italy, P599.
10. Zesiewicz TA, Strom JA, Borenstein AR, Hauser RA, Cimino CR, Fontanet H, Cintron C,
Staffetti JF, Dunne PB, Sullivan KL. Heart Failure in Parkinson’s Disease: Analysis of the United
States Medicare Current Beneficiary Survey, 1997-1999. Presented at 55th American Academy of
Neurology, Honolulu, Hawaii, April 1, 2003.
11. Carter SN, Borenstein A, Schwartz S, Zesiewicz TA. Neutraceutical Use in Parkinson’ s Disease
Patients. Parkinson Study Group Symposium, American Neurological Association, October 19,
2003 San Francisco, California.
12. Zesiewicz TA, Carter SN, Dunne PB, Staffetti JF, Barber K, Hauser RA. Initial management of
Parkinsons’s Disease. Presented at the Movement Disorder Society's 7th International Congress
of Parkinson's Disease and Movement Disorders, November 10-14, 2002, Fontainebleau Hilton,
Miami, Florida, USA.
xx
13. Cimino CR, Zesiewicz TA, Patel A, Weiner WJ. Depression scales in PD. PSG Forum of
American Neurological Association Chicago, 2001.
14. Zesiewicz TA, Patel A, Cimino C, Leaverton P, Staffetti J, Hauser RA. Analysis of United States
Social Security Disability Insurance in Parkinson's disease patients, 1999. Accepted to American
Academy of Neurology 2001, Philadelphia, PA, presented May 8, 2001.
15. Zesiewicz TA, Cimino C, Garner N, Leaverton PL, Hauser RA. Driving Safety in Parkinson's
disease. Neurology 2000.
16. Wendell CM, Hauser RA, Nagaria MH, Sanchez-Ramos JR, Zesiewicz TA. Chief complaints of
patients with Parkinson’s disease. Neurology 1999; 52 (Suppl 2);A90-91.
17. Zesiewicz TA, Hauser RA, Helal M. Sildenafil Citrate (Viagra) for the treatment of erectile
dysfunction in men with Parkinson’s disease. Neurology 1999; 52 (Suppl 2):A215-216.
18. Zesiewicz TA, Cardozo F, Malek A, Willing A, Sanchez-Ramos J, Hauser RA. Effect of chronic
sertraline administration on striatal dopamine metabolism and turning behavior in unilateral 6OHDA lesioned rats. Accepted to Parkinson Study Group Forum on American Neurological
Association, Montreal, Canada, October 1998.
19. Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES,
Factor SA. Evaluation of a new home diary to assess functional status in Parkinson’s disease
patients with fluctuations and dyskinesia. Movement Disorders 1997;12:843.
20. Hauser RA, Anderson WMcD, Friedlander J, Zesiewicz TA, Gauger LL. Somnolence associated
with pramipexole therapy in Parkinson’s disease. Movement Disorders 1997;12:845.
21. Hauser RA, Zesiewicz TA, Friedlander J, Seeberger LC, O’Brien CF, Adler CH, Molho ES,
Factor SA. Impact of different severities of dyskinesia on patient-defined functional status in
Parkinson’s disease. Movement Disorders 1997;12:843.
22. Zesiewicz TA, Naidu KA, Baker M, Pedregal A, Prockop L, Hauser RA. Effect of amitriptyline,
fluoxetine, and sertraline on dopamine concentration in rat striatum. Movement Disorders
1997;12:840.
23. Hauser RA and Zesiewicz TA. Manganese and liver disease. Movement Dis 1996;11:589.
24. Hauser RA and Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease.
Movement Disorders 1996;5:603.
25. Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Manganese intoxication
may cause neurologic dysfunction in chronic liver disease. Neurology 1995;45 (S4):A369-370.
26. Hauser RA, Zesiewicz TA, Olanow CW. Manganese overload may cause the clinical and
magnetic resonance imaging abnormalities of chronic liver disease. Movement Disorders 1994;9
(suppl 1):118.
xxi
27. Cimino CR, Soety EM, Zesiewicz TA, Patel A. Depression in Parkinson's disease: cognitive
versus somatic symptoms. Poster submitted to American Psychological Association, San
Francisco, CA.
28. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA. Pramipexole-induced somnolence and
episodes of daytime sleep. Movement Disorders.
29. Hauser RA, Wahba MN, Anderson WM, Zesiewicz TA. Modafinil Treatment of Pramipexoleassociated Somnolence. Movement Disorders.
30. Soety EM, Cimino CR, Zesiewicz TA, Patel A. Use of Geriatric Depression Scale short forms in
Parkinson's disease patients. Poster submitted to annual convention of American Psychological
Association.
BOOK CHAPTERS:
1. Hauser RA, Zesiewicz TA. Management of early Parkinson’s disease. Medical Clinics of North
America. In Press.
2. Zesiewicz TA, Hauser RA. Management of Parkinson’s disease in the elderly. In Meara J, Koller
W, eds. Parkinson’s Disease and Parkinson’s Syndrome in the Elderly. Cambridge University
Press. 2007; 134-164.
3. Zesiewicz TA, Hauser RA. Treatment of Parkinson’s Disease. Continuum 2006.
4. Wahba M, Zesiewicz T, Hauser RA. Catechol-O-Methyltransferase Inhibitors in the Treatment of
Parkinson’s Disease. In: Ebadi M and Pfieffer R, eds. Parkinson’s Disease. Boca Raton, Florida:
CRC Press. 2005:(55)705-712.
5. Wahba M, Zesiewicz TA, Hauser RA. Catechol-O-methyltransferase (COMT) Inhibitors in the
Treatment of Parkinson’s Disease. 2004
6. Zesiewicz TA, Hauser RA. MAO inhibition for the treatment of Parkinson’s disease. Parkinson's
Disease: Diagnosis and Clinical Management by Stewart A. Factor D.O., William J. Weiner M.D,
New York: Demos Press. 2002:365-378.
7. Zesiewicz TA, Hauser RA. MAO Inhibitors and Parkinson's disease. In Weiner WJ, Factor SA,
eds. Parkinson's Disease at the Millenium, 2000.
BOOKS:
1. Hauser RA, Zesiewicz TA. Lyons K, Pahwa R, Parkinson’s Disease: Questions and Answers.
Fifth Edition. Merit Publishing, London 2006.
2. Brunton S. Parkinson's Disease Treatment Trends for Primary Care Provider, 2005.
3. Hauser RA, Lyons K, Pahwa R, Zesiewicz TA. Parkinson’s Disease:Questions and Answers.
Fourth Edition. Merit Publishing, London 2003.
xxii
4. Hauser RA, Zesiewicz TA. Parkinson’s Disease: Questions and Answers. Third Edition. Merit
Publishing, London 2000.
5. Hauser RA, Zesiewicz TA. Parkinson’s Disease: Questions and Answers. Second Edition. Merit
Publishing, London 1997.
6. Hauser RA, Pahwa R, Lyons K, Zesiewicz TA, Golbe L. Parkinson’s Disease: Questions and
Answers. Fourth Edition. Merit Publishing, London 2003.
NATIONAL PRESENTATIONS
Zesiewicz TA. Plenary Session of Movement Disorders Society, June 2011, Toronto, Canada.Review of
Evidence Based Medicine.
Zesiewicz, TA. Friedreich’s Ataxia and Varenicline: Double-blind, placebo-controlled trial. American
Academy of Neurology Integrated Neuroscience Session, Honolulu, Hawaii, April 2011.
Sullivan KL, Ward CL, Siraj S, Ortega M, Staffetti JF, Zesiewicz TA. Sexual dysfunction and driving
status are important predictors of marital satisfaction in Parkinson’s disease. 59th American
Academy of Neurology Annual meeting, April 29-May 5 2007, Boston, Massachusetts (May 1st
Poster Session) P01:124.
Sullivan KL, Ward CL, Hauser RA, Dunne PB, Zesiewicz TA. Prevalence and treatment of non-motor
symptoms in Parkinson’s disease. 58th American Academy of Neurology Annual meeting, April
1-8, 2006, San Diego, California. Presented on Wednesday, April 5th, 2006. Poster Session
P04:031.
Zesiewicz TA, Ward CL, Staffetti JF, Dunne PB, Sullivan KL. A double-blind, placebo-controlled trial of
Zonisamide (Zonegran) in the treatment of essential tremor. 58th American Academy of
Neurology April 1-8, 2006, San Diego, California. Presented on Wednesday, April 5, 2006.
S33:004.
Zesiewicz TA, Sullivan KL, Hauser RA, Behrouz R, Sanchez-Ramos JR. Levetiracetam (Keppra) in the
Treatment of Choreiform Movements in Huntington's Disease. American Academy of Neurology,
Miami, April 12, 2005.
Zesiewicz TA, Sullivan KL, Maldonado JA, Tatum WO, Hauser RA. Levetiracetam (Keppra) in the
Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease. Presented at 56th American
Academy of Neurology, San Francisco, CA 2004.
Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. A Double-blind, Randomized Trial of
Tegaserod (Zelnorm) in the Treatment of Constipation in Parkinson’s Disease. MDS
Congress, June 15, 2004, at the Palazzo dei Congressi, Rome, Italy, P599.
Zesiewicz TA, Guinta B, Hauser RA, Hoffman M, Wallach P, Sullivan KL. Levodopa-Induced
Hyperhomocysteinemia and Cardiovascular Dysfunction in Parkinsons Disease. MDS
Congress, June 15, 2004, at the Palazzo dei Congressi, Rome, Italy, P599.
xxiii
American Academy of Neurology Course on Movement Disorders: Presented lecture on Essential Tremor
55th Annual Meeting of the American Academy of Neurology. Honolulu, Hawaii. April 4, 2003.
Zesiewicz TA, Cimino CR, Gardner NM, Leaverton P, Hauser RA. Driving Safety in Parkinson’s
Disease. Platform Presentation by Zesiewicz TA. 52nd Annual Meeting of the American
Academy of Neurology. San Diego, California. May 5, 2000.
Wendell CM, Hauser RA, Nagaria MH, Sanchez-Ramos JR, Zesiewicz TA. Chief complaints of patients
with Parkinson’s disease. Platform Presentation by Hauser RA. 51st Annual Meeting of the
American Academy of Neurology. Toronto, Ontario, Canada. April 20, 1999.
Zesiewicz TA, Cardozo F, Malik A, Willing A, Sanchez-Ramos J, Hauser RA. Effect of chronic
sertraline administration on striatal dopamine metabolism and turning behavior in unilateral 6OHDA lesioned rats. PSG section of American Neurological Association, Montreal, Canada,
October 1998.
Hauser RA, Anderson WMcD, Friedlander J, Zesiewicz TA, Gauger LL. Somnolence associated with
pramipexole therapy in Parkinson’s disease. Eleventh Annual Symposia on Etiology,
Pathogenesis, and Prevention of Parkinson’s disease and Hyperkinetic Movement Disorders. San
Diego, CA, September 28, 1997.
Hauser RA, Zesiewicz TA, Friedlander J, Seeberger LC, O’Brien CF, Adler CH, Molho ES, Factor SA.
Impact of different severities of dyskinesia on patient-defined functional status in Parkinson’s
disease. Eleventh Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s
disease and Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997.
Zesiewicz TA, Naidu KA, Baker M, Pedregal A, Prockop L, Hauser RA. Effect of amitriptyline,
fluoxetine, and sertraline on dopamine concentration in rat striatum. Poster Presentation. Eleventh
Annual Symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s disease and
Hyperkinetic Movement Disorders. San Diego, CA, September 28, 1997.
Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson’s disease. Poster
Presentation. Tenth annual symposia on Etiology, Pathogenesis, and Prevention of Parkinson’s
disease. Miami, FL, October 13, 1996.
Hauser RA, Zesiewicz TA, Martinez C, Rosemurgy AS, Olanow CW. Manganese Intoxication May
Cause Neurologic Dysfunction in Chronic Liver Disease. Poster Presentation. 47th Annual
Meeting of the American Academy of Neurology. Seattle, Washington. May 11, 1995.
Hauser RA, Zesiewicz TA, Olanow CW. Manganese Overload May Cause the Clinical and Magnetic
Resonance Imaging Abnormalities of Chronic Liver Disease. Poster Presentation. Third
International Congress of Movement Disorders. Orlando, Florida. November 9, 1994.
INVITED SPEAKER - Regional Presentations
Pramipexole Advisory Board Symposium, Miami Florida, December 4-5, 2004.
Boehinger Ingelheim: Diagnosis and Treatment of Parkinson’s Disease. St. Elizabeth’s Hospital, Boston
Massachusetts, November 10, 2004
xxiv
Glaxo SmithKline: Diagnosis and Treatment of Parkinson’s Disease. Presentation to ARNP Association,
sponsored by College of Nursing, University of South Florida, March 20, 2004.
Boerhinger Ingelheim: Diagnosis and Treatment of Parkinson’s Disease. Baptist Hospital, Nashville, TN,
May 22, 2004.
Medical Management of Parkinson’s Disease. NPF PARKINSON’S DISEASE PATIENT
SYMPOSIUM, March 27th 2004, University of South Florida, College of Public Health, 13201
Bruce B. Downs, Tampa, FL 33612.
Diagnosis and Treatment of Parkinson’s Disease: 2nd Annual Spring Symposium for Nurse Practitioners,
March 19 - 20, 2004, Dr. Blaise S. Alfano Conference and Banquet Center, Tampa, Florida.
Treatment Strategies in Parkinson's Disease. Sponsored by Novartis Pharmaceuticals. West Palm Beach,
FL. February 3, 2000.
NATIONAL COURSES TAUGHT
Parkinson’s Disease Seminar for Patients and Caregivers. In association with Tampa General Healthcare
and the University of South Florida. Tampa General Hospital. Tampa, Florida, December 3,
1994.
National Parkinson’s Disease sponsored seminar on Parkinson’s Disease. In association with the
University of South Florida. Hyatt Regency, Tampa, Florida January 25, 1997.
National Parkinson’s Disease sponsored seminar on Parkinson’s Disease. Hyatt Regency, Orlando,
Florida February 1998
Movement Disorder’s Course for Parkinson’s Disease. Moderator: William J. Weiner. American
Academy of Neurology. Honolulu, Hawaii. April 4, 2003.
Mirapex Regional Training Session, Dallas TX, September 17, 2003, Invited Lecturer for Parkinson’s
Disease.
COURSES AND SEMINARS
Parkinson’s Disease Seminar for Patients and Caregivers. In association with Tampa General Healthcare
and the University of South Florida. College of Public Health. Tampa General Hospital. Tampa,
FL. March 23, 1999.
Dr. Theresa Zesiewicz – Overview of Parkinson's Disease
Dr. Juan Sanchez-Ramos – Clues to the Etiology of Parkinson's Disease
Dr. Robert Hauser – Medical Management of Parkinson's Disease
Dr. Fernando Vale - Pallidotomy for Parkinson's Disease
Dr. Donald Smith – Stimulation Surgeries for Parkinson's Disease
Dr. Thomas Freeman – Cell Transplantation Strategies for Parkinson's Disease
350 in attendance
Parkinson’s Disease Seminar for Patients and Caregivers. In association with Tampa General Healthcare
and the University of South Florida. College of Public Health. Tampa General Hospital. Tampa,
FL. March 14, 1998.
xxv
Dr. Juan Sanchez-Ramos – Clues to the Etiology of Parkinson's Disease
Dr. Robert Hauser – Medical Management of Parkinson's Disease
Dr. Theresa Zesiewicz – Treatment of Secondary Symptoms of Parkinson's Disease
Dr. Fernando Vale – Pallidotomy for Parkinson's Disease
Dr. Donald Smith – Stimulation Surgeries for Parkinson's Disease
Dr. Thomas Freeman – Cell Transplantation Strategies for Parkinson's Disease
400 in attendance
Parkinson’s Disease Seminar for Patients and Caregivers. In association with Tampa General Healthcare
and the University of South Florida. Tampa General Hospital. Tampa, FL. December 3, 1994.
Dr. Theresa Zesiewicz – Overview of Parkinson's Disease
Dr. Robert Hauser – Advances in Medical Therapy of Parkinson's Disease
Dr. Thomas Freeman – Fetal Transplantation for Parkinson's Disease
Dr. Donald Smith – Thalamic Stimulation for Tremor
282 in attendance
MEDIA APPEARANCES
Medtronic Video for Deep Brain Stimulation in Essential Tremor, 2005
Levetiracetam in the Use of Levodopa-Induced Dyskinesia in Parkinson’s Disease:
Aging & Elder Health Week, Study suggests levetiracetam may benefit patients with Parkinson's
disease, May 30, 2004
Medical Letter on the CDC & FDA, Study suggests levetiracetam may benefit patients with
Parkinson's disease, May 30, 2004
Law & Health Weekly, Study suggests levetiracetam may benefit patients with Parkinson's
disease, May 29, 2004
NewsRX, Study suggests levetiracetam may benefit patients with Parkinson's disease. May 29,
2004
Obesity, Fitness & Wellness Week, Study suggests levetiracetam may benefit patients with
Parkinson's disease, May 29, 2004
Health Business Week, Study suggests levetiracetam may benefit patients with Parkinson's
disease, May 28, 2004
Drug Week, Study suggests levetiracetam may benefit patients with Parkinson's disease, May 28,
2004
Medicine & Law Weekly, Study suggests levetiracetam may benefit patients with Parkinson's
disease, May 28, 2004
Biotech Law Weekly, Study suggests levetiracetam may benefit patients with Parkinson's disease,
May 28, 2004
xxvi
Biotech Week, Study suggests levetiracetam may benefit patients with Parkinson's disease, May
26, 2004
Elder Law Weekly, Study suggests levetiracetam may benefit patients with Parkinson's disease,
May 26, 2004
Health & Medicine Week, Study suggests levetiracetam may benefit patients with Parkinson's
disease, May 24, 2004
Pain & Central Nervous System Week, Study suggests levetiracetam may benefit patients with
Parkinson's disease, May 24, 2004
CNS Drug News, Study suggests levetiracetam may benefit patients with PD, May 4, 2004
Doctor's Guide: AAN: Levodopa-Induced Dyskinesias Relieved With Anti-Epileptics, By Ed
Susman, April 30, 2004
The Medical Herald - May issue contains coverage May, 2004
University of South Florida HSC News, Pilot study suggest antiepileptic drug may benefit
patients with Parkinson's disease. May 6, 2004
WUSF - FM radio in Tampa - Dr. Zesiewicz was interviewed by Tom Parkinson 10:00am May
20, 2004
WTUT - Fox TV in Tampa – Interview May 20, 2004
Biocompare.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients
With Parkinson's Disease, April 29, 2004
Boerse (nachrichten.boerse.de), New Study Suggests Antiepileptic Drug Levetiracetam May
Benefit Patients With Parkinson's Disease, April 29, 2004
CBS MarketWatch.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit
Patients With Parkinson's Disease, April 29, 2004
DallasNews.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients
With Parkinson's Disease, April 29, 2004
Eonlabs.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients With
Parkinson's Disease, April 29, 2004
Excitemoney.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients
With Parkinson's Disease, April 29, 2004\
Finance Canada.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit
Patients With Parkinson's Disease,
April 29, 2004
FindHealthNews.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit
Patients With Parkinson's Disease, April 29, 2004
xxvii
iWon (money.iwon.com), New Study Suggests Antiepileptic Drug Levetiracetam May Benefit
Patients With Parkinson's Disease, April 29, 2004
Latinvision.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients
With Parkinson's Disease, April 29, 2004
Lycosfinance.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients
With Parkinson's Disease, April 29, 2004
MedicalDevices.org, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit
Patients With Parkinson's Disease, April 29, 2004
National Hispanic Corporate Council.com, New Study Suggests Antiepileptic Drug
Levetiracetam May Benefit Patients With Parkinson's Disease, April 29, 2004
Northwest Parkinson's Foundation.org, New Study Suggests Antiepileptic Drug Levetiracetam
May Benefit Patients With Parkinson's Disease, April 29, 2004
P&Tcommunity.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit
Patients With Parkinson's Disease, April 29, 2004
TXCN.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients With
Parkinson's Disease, April 29, 2004
Ventura County Star.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit
Patients With Parkinson's Disease, April 29, 2004
Yahoo.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients With
Parkinson's Disease, April 29, 2004
Yahoo Biz.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients
With Parkinson's Disease, April 29, 2004
Yahoo Canada.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit Patients
With Parkinson's Disease, April 29, 2004
Yahoo UK and Ireland.com, New Study Suggests Antiepileptic Drug Levetiracetam May Benefit
Patients With Parkinson's Disease, April 29, 2004
WYUU interview on Parkinson’s disease; October 15, 1995
WFLA channel 8 television interview. Janet Reno and Parkinson’s disease; November 2, 1995